<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010389470</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010389470</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling the Onset and Offset of Dental Pain Relief by Ibuprofen</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Li</surname><given-names>Hanbin</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Mandema</surname><given-names>Jaap</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Wada</surname><given-names>Russell</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Jayawardena</surname><given-names>Shyamalie</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Desjardins</surname><given-names>Paul</given-names></name>
<degrees>DMD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Doyle</surname><given-names>Geraldine</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Kellstein</surname><given-names>David</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010389470">Quantitative Solutions Inc, Menlo Park, California (Dr Li, Dr Mandema, Dr Wada)</aff>
<aff id="aff2-0091270010389470">Pfizer Consumer Healthcare, Madison, New Jersey (Dr Jayawardena, Dr Desjardins, Dr Doyle, Dr Kellstein)</aff>
<author-notes>
<corresp id="corresp1-0091270010389470">Hanbin Li, PhD, Quantitative Solutions Inc, 845 Oak Grove, Suite 100, Menlo Park, CA 94025; e-mail: <email>hli@wequantify.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>89</fpage>
<lpage>101</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>6</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>10</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Onset and offset of dental pain relief by ibuprofen following third molar extraction were modeled in a randomized, double-blind, placebo-controlled, parallel-group, 8-hour study of patients receiving either a novel effervescent ibuprofen tablet (400 mg; N = 30), standard ibuprofen tablets (Nurofen<sup>®</sup> 2 × 200 mg; N = 22), or placebo (N = 37). An Emax model was fit to pain relief scores. Linear hazard models were used to analyze the time to first perceptible relief (TFPR), the time to meaningful pain relief (TMPR), and time to remedication (REMD). Nomograms were created to correlate TFPR, TMPR, and REMD with different ibuprofen pharmacokinetic profiles. Effervescent ibuprofen was absorbed rapidly with 95% completion within 15 minutes. Maximum pain relief score by ibuprofen was 1.8 units greater than placebo, with an EC50 (effect-site) for ibuprofen concentration of 10.2 µg·mL<sup>−1</sup>. The likelihood to achieve TFPR and TMPR was doubled for every 10 µg·mL<sup>−1</sup> increase in ibuprofen plasma concentration. REMD risk decreased 40-fold as the categorical pain relief score increased from 0 to 3. Rapid absorption of ibuprofen effervescent resulted in an earlier TFPR and TMPR, and a lower REMD rate than standard ibuprofen. The nomograms may be useful in predicting the onset and offset of new faster acting ibuprofen formulations, based on pharmacokinetic profiles.</p>
</abstract>
<kwd-group>
<kwd>Ibuprofen effervescent</kwd>
<kwd>third molar extraction</kwd>
<kwd>dental pain</kwd>
<kwd>analgesia</kwd>
<kwd>onset</kwd>
<kwd>offset</kwd>
<kwd>hazard model</kwd>
<kwd>nomogram</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Ibuprofen (2-[4-isobutylpenyl] propionic acid) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for analgesia, antipyresis, and various arthritic conditions. It was the first nonaspirin NSAID approved to be sold over-the-counter (OTC) and is widely used globally for pain relief.<sup><xref ref-type="bibr" rid="bibr1-0091270010389470">1</xref>,<xref ref-type="bibr" rid="bibr2-0091270010389470">2</xref></sup> The analgesic efficacy of ibuprofen has been extensively evaluated. Previous studies have shown that a single dose of ibuprofen tablets (400 mg) provides superior analgesic efficacy compared with acetaminophen (1000 mg) in several different clinical pain models (ie, third molar extraction,<sup><xref ref-type="bibr" rid="bibr3-0091270010389470">3</xref></sup> tension-type headache,<sup><xref ref-type="bibr" rid="bibr4-0091270010389470">4</xref></sup> muscle pain,<sup><xref ref-type="bibr" rid="bibr5-0091270010389470">5</xref></sup> sore throat,<sup><xref ref-type="bibr" rid="bibr6-0091270010389470">6</xref></sup> and postpartum episiotomy pain<sup><xref ref-type="bibr" rid="bibr7-0091270010389470">7</xref></sup>). Ibuprofen tablets of 200 or 400 mg have also been shown to provide superior analgesic efficacy compared with aspirin tablets of 325 mg or 650 mg following third molar extraction.<sup><xref ref-type="bibr" rid="bibr8-0091270010389470">8</xref></sup></p>
<p>Laska et al<sup><xref ref-type="bibr" rid="bibr9-0091270010389470">9</xref></sup> demonstrated that increased serum ibuprofen levels are correlated with greater analgesic efficacy, especially during the first few hours after dosing. Accordingly, continuous efforts have been made during the past few decades to optimize ibuprofen formulations for faster onset of analgesia. Solubilized formulations of ibuprofen liquigels (also known as liquid filled capsules or soft gelatin capsules) are marketed in multiple countries. One such formulation (Advil<sup>®</sup> Liqui-Gels<sup>®</sup>) is absorbed faster than conventional ibuprofen tablets<sup><xref ref-type="bibr" rid="bibr10-0091270010389470">10</xref></sup> and provides faster pain relief as well as superior overall efficacy compared with acetaminophen tablets.<sup><xref ref-type="bibr" rid="bibr11-0091270010389470">11</xref>–<xref ref-type="bibr" rid="bibr13-0091270010389470">13</xref></sup> Ibuprofen salts, such as ibuprofen arginate and ibuprofen sodium, dissolve rapidly in the gastrointestinal tract and have a faster onset of analgesia than standard ibuprofen tablets.<sup><xref ref-type="bibr" rid="bibr14-0091270010389470">14</xref>–<xref ref-type="bibr" rid="bibr17-0091270010389470">17</xref></sup> Effervescent forms of ibuprofen have also been developed to dissolve rapidly in fluid before ingestion. An effervescent ibuprofen granule formulation was shown to provide faster onset of analgesia than a standard ibuprofen tablet.<sup><xref ref-type="bibr" rid="bibr18-0091270010389470">18</xref></sup> Although 1 formulation of an effervescent ibuprofen tablet was absorbed faster than conventional ibuprofen tablets<sup><xref ref-type="bibr" rid="bibr19-0091270010389470">19</xref></sup> another effervescent tablet was not.<sup><xref ref-type="bibr" rid="bibr20-0091270010389470">20</xref></sup> Recently, a novel effervescent ibuprofen tablet has been developed that provides absorption of ibuprofen that is faster than standard ibuprofen tablets and at least as fast as ibuprofen liquigels (data on file, Pfizer Consumer Healthcare).</p>
<p>Since previous studies have shown that more rapid ibuprofen absorption translates into more rapid pain relief,<sup><xref ref-type="bibr" rid="bibr14-0091270010389470">14</xref>–<xref ref-type="bibr" rid="bibr17-0091270010389470">17</xref></sup> pharmacokinetic (PK) data were collected from a subgroup of patients in this study of third molar extraction pain aiming to correlate the onset and offset of pain relief with the PK profiles of the 2 ibuprofen formulations. Pain following third molar extraction is a widely accepted model for assessing acute analgesic efficacy and is generalizable to other types of acute pain. The purpose of this analysis was to develop a practical method that would facilitate the assessment of potential faster acting ibuprofen formulations in drug development. Nomograms of onset and offset of pain relief were developed for typical patients so that clinical outcomes of the new ibuprofen formulations could be predicted based on their PK data.</p>
<sec id="section1-0091270010389470" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010389470">
<title>Study Design and Data</title>
<p>The data used for this pharmacokinetic/pharmacodynamic (PKPD) analysis was collected in a single-center, inpatient, single-dose, randomized, placebo-controlled, double-blind, parallel-group trial conducted at SCIREX/Premier Research Centers in Austin, Texas. The study was conducted in full conformance with the principles of the Declaration of Helsinki (as amended in Tokyo, Venice, and Hong Kong) and in accordance with ICH Good Clinical Practice guidelines. The protocol and informed consent form were reviewed and approved by Coast Independent Review Board (Lake Forest, California) prior to initiation of the study. The study was registered with clinicaltrials.gov (NCT# 00631111).</p>
<p>A total of 262 healthy male or female subjects, ages 16 to 40 years, were randomized to receive a single oral dose of ibuprofen effervescent tablets of 400 mg, Nurofen<sup>®</sup> tablets of 2 × 200 mg, another nonibuprofen analgesic, or placebo for relief of pain following surgical extraction of 2 or more third molars, at least 1 of which was required to be a partial or full bony mandibular impaction. To maintain the double-blinded conditions of the study, study medication was administered to each subject by a disinterested third party otherwise not involved in the trial. Each subject swallowed 2 tablets (active or placebo) with liquid containing a dissolved effervescent tablet (active or placebo), and was blindfolded during study drug administration. Before the subject was administered the study drug, his or her postsurgical pain intensity was required to be moderate to severe at baseline, as rated on a 4-point (0-3 for none, mild, moderate, and severe) categorical pain severity rating scale, and confirmed by a score of at least 50 mm on a 100-mm visual analog scale (VAS).</p>
<p>Blood samples were drawn via an indwelling venous catheter from the first 125 subjects that consented to blood sampling at predose, 10, 15, 20, 25, 30, 45, 60, and 90 minutes, at 2, 3, 4, 5, 6, 7, and 8 hours postdose, and immediately prior to remedication (REMD) with rescue drug (if necessary). PK data collected from 36 patients on nonibuprofen analgesic were not included in this analysis. Plasma samples from subjects dosed with the 2 ibuprofen formulations were assayed for racemic ibuprofen using high performance liquid chromatography with tandem mass spectrometry detection by PPD Development (Richmond, Virginia). Analysis of racemic ibuprofen was performed because this level accurately reflects the relative amount of the active S-enantiomer. Five-point categorical pain relief (0-4 for none, a little, some, a lot, and complete relief, respectively) and 4-point pain categorical pain severity scores were self-reported by subjects at baseline, 15, 30, 45, 60, and 90 minutes postdose, and then hourly until 8 hours postdose. Time to first perceptible relief (TFPR) and time to meaningful pain relief (TMPR) were measured by stopwatches. Patients were given 2 stopwatches 3 to 4 minutes postdose and instructed to stop the first covered stopwatch when they first began to feel any pain relief, and to stop the second watch when they felt meaningful relief. Time to REMD (rescue) with an alternative analgesic, if it occurred, was also recorded. Patients were encouraged to postpone REMD until after 1 hour postdose. All observed or reported adverse experiences were recorded.</p>
</sec>
<sec id="section3-0091270010389470">
<title>PK Model</title>
<p>The PKs of ibuprofen are characterized by a 1- compartment system with first-order absorption, first-order elimination, and an absorption lag time:</p>
<p><disp-formula id="disp-formula1-0091270010389470">
<label>(1)</label>
<mml:math display="block" id="math1-0091270010389470">
<mml:mrow>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>D</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>e</mml:mi>
<mml:mo>×</mml:mo>
<mml:mi>C</mml:mi>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>k</mml:mi>
<mml:mi>a</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mi>k</mml:mi>
<mml:mi>a</mml:mi>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mi>λ</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>k</mml:mi>
<mml:mi>a</mml:mi>
</mml:msub>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>ε</mml:mi>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010389470" xlink:href="10.1177_0091270010389470-eq1.tif"/>
</disp-formula></p>
<p>where <italic>C</italic><sub><italic>p</italic></sub>(<italic>t</italic>) is the ibuprofen plasma concentration at time <italic>t</italic>, time after dosing minus the absorption lag time(<italic>T</italic><sub><italic>lag</italic></sub>), <italic>C</italic> = 1/(<italic>V/F</italic>) is the coefficient, λ = <italic>CL/V</italic> is the exponent of ibuprofen PKs, <italic>k</italic><sub><italic>a</italic></sub> is the first-order absorption rate constant, and ε is normally distributed residual variability.</p>
<p>The PK model was parameterized with clearance (<italic>CL/F</italic>), central volume of distribution (<italic>V/F</italic>), absorption rate constant (<italic>k</italic><sub><italic>a</italic></sub>), and lag time (<italic>T</italic><sub><italic>lag</italic></sub>). PK models were estimated separately for effervescent and standard ibuprofen. The difference in <italic>k</italic><sub><italic>a</italic></sub> and <italic>T</italic><sub><italic>lag</italic></sub> values reflect their difference in absorption. Model parameters were estimated using the nonlinear mixed-effects (nlme) modeling function in S-plus<sup>®</sup> (version 6.2, Insightful Corp, Seattle, Washington). Subject variability was assumed to be additive during the absorption phase (time &lt; 0.75 hours for effervescent ibuprofen, and time &lt; 2 hours for standard ibuprofen) and log-normal thereafter. The log-normal residual model is more suitable for the elimination phase, while it often under-predicts the peak concentrations. Using the combined residual model enables the model to capture both absorption and elimination phases.</p>
<p>The interindividual variability in the PK is modeled according to an exponential variance model assuming the parameters are log-normal distributed:</p>
<p><disp-formula id="disp-formula2-0091270010389470">
<label>(2)</label>
<mml:math display="block" id="math2-0091270010389470">
<mml:mrow>
<mml:msub>
<mml:mi>ϕ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>η</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010389470" xlink:href="10.1177_0091270010389470-eq2.tif"/>
</disp-formula></p>
<p>in which ϕ<sub><italic>i</italic></sub> is the vector of PK parameters of the <italic>i</italic><sup><italic>th</italic></sup> individual, θ is the vector of population mean PK parameters, and η<sub><italic>i</italic></sub> is the random difference between ϕ<sub><italic>i</italic></sub> and θ. η<sub><italic>i</italic></sub> is assumed to be normally distributed with mean zero and variance ω<sup>2</sup>. Because the purpose of PK modeling was to characterize the PK in healthy subjects, no covariates were included in the ibuprofen PK modeling.</p>
</sec>
<sec id="section4-0091270010389470">
<title>Pain Relief Model</title>
<p>The pain relief model considers the categorical pain relief score as a continuous variable.<sup><xref ref-type="bibr" rid="bibr21-0091270010389470">21</xref></sup> In <xref ref-type="disp-formula" rid="disp-formula3-0091270010389470">Equation 3</xref>, pain relief (PR) was modeled as the sum of the placebo effect and the drug effect:</p>
<p><disp-formula id="disp-formula3-0091270010389470">
<label>(3)</label>
<mml:math display="block" id="math3-0091270010389470">
<mml:mrow>
<mml:mi>P</mml:mi>
<mml:mi>R</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>d</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>ε</mml:mi>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010389470" xlink:href="10.1177_0091270010389470-eq3.tif"/>
</disp-formula></p>
<p>where <italic>PR(t)</italic> is the pain relief score at time <italic>t</italic>, <italic>f</italic><sub><italic>p</italic></sub><italic>(t)</italic> represents the pain relief from the placebo, <italic>f</italic><sub><italic>d</italic></sub>(<italic>C</italic><sub><italic>e</italic></sub>) represents the pain relief by ibuprofen, and ε is the residual variability assumed to be normally distributed with mean zero and variance σ<sup>2</sup>. Pain relief by the placebo alone is given as:</p>
<p><disp-formula id="disp-formula4-0091270010389470">
<label>(4)</label>
<mml:math display="block" id="math4-0091270010389470">
<mml:mrow>
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mrow>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>k</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0091270010389470" xlink:href="10.1177_0091270010389470-eq4.tif"/>
</disp-formula></p>
<p>in which <italic>P</italic><sub><italic>max</italic></sub> is the maximum placebo effect and <italic>k</italic> is the first-order rate constant of placebo effect. A sigmoid-Emax model was used to characterize the relationship of ibuprofen concentration and its effect on pain relief:</p>
<p><disp-formula id="disp-formula5-0091270010389470">
<label>(5)</label>
<mml:math display="block" id="math5-0091270010389470">
<mml:mrow>
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>d</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>E</mml:mi>
<mml:mrow>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msubsup>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>γ</mml:mi>
</mml:msubsup>
</mml:mrow>
<mml:mrow>
<mml:msubsup>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>γ</mml:mi>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mi>E</mml:mi>
<mml:msubsup>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
<mml:mi>γ</mml:mi>
</mml:msubsup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0091270010389470" xlink:href="10.1177_0091270010389470-eq5.tif"/>
</disp-formula></p>
<p>in which <italic>E</italic><sub><italic>max</italic></sub> is the maximum pain relief by ibuprofen, <italic>EC</italic><sub><italic>50</italic></sub> is the drug concentration at half-maximal effect, and γ reflects the steepness of the relationship. <italic>C</italic><sub><italic>e</italic></sub> denotes an effect-site ibuprofen concentration given by:</p>
<p><disp-formula id="disp-formula6-0091270010389470">
<label>(6)</label>
<mml:math display="block" id="math6-0091270010389470">
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>k</mml:mi>
<mml:mrow>
<mml:mi>e</mml:mi>
<mml:mi>o</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>e</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0091270010389470" xlink:href="10.1177_0091270010389470-eq6.tif"/>
</disp-formula></p>
<p>where <italic>k</italic><sub><italic>eo</italic></sub> is the first-order equilibration rate constant that characterizes the delay between plasma and effect-site concentration, and <italic>C</italic><sub><italic>p</italic></sub><italic>(t)</italic> is the plasma ibuprofen concentration at time <italic>t</italic>. Between measured time points, plasma ibuprofen concentration was approximated by linear interpolation of the observed values. The model parameters were estimated by mixed effects analysis using NONMEM (version VI, level 1.0 Globomax, Hanover, Maryland).</p>
</sec>
<sec id="section5-0091270010389470">
<title>TFPR and TMPR Hazard Models</title>
<p>The TFPR and TMPR were modeled as survival variables using linear hazard models. The hazard rate (λ) is assumed to be a constant for patients treated with placebo. Although an indirect response model could be more physiologically meaningful for the onset of pain relief by ibuprofen, the increase of TFPR and TMPR hazard rates were modeled as a direct response to the plasma ibuprofen concentration because there was only a single observation for each patient (if he or she ever reached TFPR or TMPR before rescue or treatment ended). For patients treated with ibuprofen, λ is a function of ibuprofen plasma concentration at time <italic>t</italic> given as the following equation:</p>
<p><disp-formula id="disp-formula7-0091270010389470">
<label>(7)</label>
<mml:math display="block" id="math7-0091270010389470">
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-0091270010389470" xlink:href="10.1177_0091270010389470-eq7.tif"/>
</disp-formula></p>
<p>where λ<sub><italic>pl</italic></sub> is the hazard rate of placebo patients, <italic>C</italic><sub><italic>p</italic></sub><italic>(t)</italic> is the plasma ibuprofen concentration at time <italic>t</italic>, and <italic>k</italic> represents the slope of the hazard rate increase with ibuprofen plasma concentration.</p>
<p>The TFPR and TMPR hazard model parameters, θ = {λ<sub><italic>pl</italic></sub>, <italic>k</italic>}, were estimated using the maximum likelihood estimator:</p>
<p><disp-formula id="disp-formula8-0091270010389470">
<label>(8)</label>
<mml:math display="block" id="math8-0091270010389470">
<mml:mrow>
<mml:mi>L</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mstyle displaystyle="true">
<mml:munder>
<mml:mo>∏</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>∈</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>c</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:munder>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:mstyle>
<mml:mstyle displaystyle="true">
<mml:munder>
<mml:mo>∏</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>∈</mml:mo>
<mml:mi>r</mml:mi>
<mml:mo>.</mml:mo>
<mml:mi>c</mml:mi>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:munder>
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mstyle>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0091270010389470" xlink:href="10.1177_0091270010389470-eq8.tif"/>
</disp-formula></p>
<p>where the uncensored data is denoted as <italic>unc</italic>., and right censored data is denoted as <italic>r.c</italic>. For an uncensored datum (ie, TFPR or TMPR occurred before the patient dropped out or the observation period ended), the probability density function (pdf) of patient <italic>i</italic> to have an event at time <italic>T</italic><sub><italic>i</italic></sub> is given as:</p>
<p><disp-formula id="disp-formula9-0091270010389470">
<label>(9)</label>
<mml:math display="block" id="math9-0091270010389470">
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>d</mml:mi>
<mml:mi>f</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>h</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">[</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-0091270010389470" xlink:href="10.1177_0091270010389470-eq9.tif"/>
</disp-formula></p>
<p>where <italic>h</italic> is the hazard density and <italic>H</italic> is the cumulative hazard, with <italic>T</italic><sub><italic>i</italic></sub> equal to the time to event for patient <italic>i</italic>. For a right-censored datum (ie, patient never reached TFPR or TMPR because of drop-out or the observation period ended) the probability of patient <italic>i</italic> not to have an event until after <italic>T</italic><sub><italic>i</italic></sub> is given as:</p>
<p><disp-formula id="disp-formula10-0091270010389470">
<label>(10)</label>
<mml:math display="block" id="math10-0091270010389470">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">[</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-0091270010389470" xlink:href="10.1177_0091270010389470-eq10.tif"/>
</disp-formula></p>
<p>where <italic>T</italic><sub><italic>i</italic></sub> equals the time of drop-out or observation ended. From <xref ref-type="disp-formula" rid="disp-formula7-0091270010389470">Equation 7</xref>, the hazard density at time <italic>T</italic><sub><italic>i</italic></sub> is derived as:</p>
<p><disp-formula id="disp-formula11-0091270010389470">
<label>(11)</label>
<mml:math display="block" id="math11-0091270010389470">
<mml:mrow>
<mml:mi>h</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula11-0091270010389470" xlink:href="10.1177_0091270010389470-eq11.tif"/>
</disp-formula></p>
<p>where <italic>C</italic><sub><italic>p</italic></sub>(<italic>T</italic><sub><italic>i</italic></sub>) is the plasma ibuprofen concentration at time <italic>T</italic><sub><italic>i</italic></sub>, and the cumulative hazard of patient at time <italic>T</italic><sub><italic>i</italic></sub> is derived as:</p>
<p><disp-formula id="disp-formula12-0091270010389470">
<label>(12)</label>
<mml:math display="block" id="math12-0091270010389470">
<mml:mrow>
<mml:mi>H</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:mi>A</mml:mi>
<mml:mi>U</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula12-0091270010389470" xlink:href="10.1177_0091270010389470-eq12.tif"/>
</disp-formula></p>
<p>where AUC<sub>0-Ti</sub> is the area under the curve of ibuprofen plasma concentration from 0 to <italic>T</italic><sub><italic>i</italic></sub>. S-plus (version 6.2) was used to estimate the hazard model parameters of TFPR and TMPR.</p>
</sec>
<sec id="section6-0091270010389470">
<title>REMD Hazard Model</title>
<p>Time to REMD is viewed as a survival variable. A patient’s probability to need REMD in the <italic>i</italic><sup>th</sup> interval (<italic>t</italic><sub><italic>i</italic></sub>, <italic>t</italic><sub><italic>i</italic>+1</sub>) is assumed to be a function of the pain relief score at the preceding measurement at time <italic>t</italic><sub><italic>i</italic></sub>. On the condition that a patient reaches the <italic>i</italic><sup><italic>th</italic></sup> interval without REMD, the probability (Pr) that a patient remains in the study during that interval is given by the following equation:</p>
<p><disp-formula id="disp-formula13-0091270010389470">
<label>(13)</label>
<mml:math display="block" id="math13-0091270010389470">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>S</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mstyle displaystyle="true">
<mml:mrow>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>+</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:munderover>
<mml:mrow>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mi>d</mml:mi>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mstyle>
<mml:mo>=</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula13-0091270010389470" xlink:href="10.1177_0091270010389470-eq13.tif"/>
</disp-formula></p>
<p>and the probability of a patient needing REMD during that interval is given as:</p>
<p><disp-formula id="disp-formula14-0091270010389470">
<label>(14)</label>
<mml:math display="block" id="math14-0091270010389470">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>≤</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>S</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula14-0091270010389470" xlink:href="10.1177_0091270010389470-eq14.tif"/>
</disp-formula></p>
<p>where <italic>T</italic> is the time from the beginning of the <italic>i</italic><sup><italic>th</italic></sup> interval (<italic>t</italic><sub><italic>i</italic></sub>), <italic>T</italic><sub><italic>dur i</italic></sub> = <italic>t</italic><sub><italic>i</italic>+1</sub>-<italic>t</italic><sub><italic>i</italic></sub> is time duration between <italic>t</italic><sub><italic>i</italic></sub> and <italic>t</italic><sub><italic>i</italic>+1</sub>, λ<sub><italic>k</italic></sub>, <italic>k</italic>∈<italic>{0, 1, 2, 3, 4}</italic> is the hazard rate specific for the pain relief score measured at the beginning of the <italic>i</italic><sup><italic>th</italic></sup> interval (<italic>t</italic><sub><italic>i</italic></sub>), <italic>S</italic> is the survival function assumed to be exponentially distributed, and θ = {λ<sub>0</sub>, λ<sub>1</sub>, λ<sub>2</sub>, λ<sub>3</sub>, λ<sub>4</sub>} are the vector of model parameters to be estimated. The model parameters θ were estimated using a maximum likelihood objective function (<italic>L</italic>) given as the following equation:</p>
<p><disp-formula id="disp-formula15-0091270010389470">
<label>(15)</label>
<mml:math display="block" id="math15-0091270010389470">
<mml:mrow>
<mml:mi>L</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mstyle displaystyle="true">
<mml:munder>
<mml:mo>∏</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>∈</mml:mo>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:munder>
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>≤</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>.</mml:mo>
<mml:mstyle displaystyle="true">
<mml:munder>
<mml:mo>∏</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>∈</mml:mo>
<mml:mi>n</mml:mi>
<mml:mi>o</mml:mi>
<mml:mo>-</mml:mo>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>m</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:munder>
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mi>d</mml:mi>
<mml:mi>u</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mstyle>
</mml:mrow>
</mml:mstyle>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula15-0091270010389470" xlink:href="10.1177_0091270010389470-eq15.tif"/>
</disp-formula></p>
<p>where <italic>remed</italic> denotes the intervals that required REMD and <italic>no-remed</italic> denotes the intervals without REMD. The <italic>nlminb</italic> function in S-plus was used to estimate the model parameters of REMD.</p>
</sec>
<sec id="section7-0091270010389470">
<title>Nomograms of TFPR and TMPR</title>
<p>Nomograms of TFPR and TMPR were created by simulation of the TFPR and TMPR hazard models at typical PK profiles following oral administration of ibuprofen. The simulation was done in S-plus using the following procedures:</p>
<list id="list1-0091270010389470" list-type="order">
<list-item><p>A matrix of size <italic>n</italic> × <italic>m</italic> was created for a series of T<sub>max</sub> (length = <italic>n</italic>) values and a series of C<sub>max</sub> values (length = <italic>m</italic>). The T<sub>max</sub> selected for this simulation ranges from 0.2 to 3.0 hours in increments of 0.1 hour, and the C<sub>max</sub> ranges from 10 to 80 µg·mL<sup>−1</sup> in increments of 10 µg·mL<sup>−1</sup>. Approximately, doses were ranged from 85 mg to 2240 mg, and the ka values were ranged from 0.3 h<sup>−1</sup> to 46.7 h<sup>−1</sup>.</p></list-item>
<list-item><p>The TFPR or TMPR at each T<sub>max</sub> and C<sub>max</sub> combination was calculated by the following steps:</p>
<list id="list2-0091270010389470" list-type="bullet"><list-item><p>Assuming PK can be described by a first-order absorption model with lag time, combinations of ibuprofen dose (mg) and its first-order absorption rate constant ka (h<sup>−1</sup>) were created to meet the targeted C<sub>max</sub> and T<sub>max</sub> combination. An absorption lag time (T<sub>lag</sub>) of 0.1 hours was selected to represent the faster absorption formulation and T<sub>lag</sub> = 0.3 hours was selected to represent the slower absorption formulation. The time course of ibuprofen plasma concentration was calculated from dose, ka, T<sub>lag</sub>, V/F, and CL/F. Neither interindividual nor intraindividual variability were included in the PK calculations.</p></list-item>
<list-item><p>From <xref ref-type="disp-formula" rid="disp-formula9-0091270010389470">Equations 9</xref>, <xref ref-type="disp-formula" rid="disp-formula11-0091270010389470">11</xref>, and <xref ref-type="disp-formula" rid="disp-formula12-0091270010389470">12</xref>, the probability of a typical patient having a TFPR or TMPR event at time <italic>t</italic> is derived as:</p>
<p><disp-formula id="disp-formula16-0091270010389470">
<label>(16)</label>
<mml:math display="block" id="math16-0091270010389470">
<mml:mrow>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo>|</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>⋅</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mo stretchy="false">[</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>λ</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>⋅</mml:mo>
<mml:mi>A</mml:mi>
<mml:mi>U</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula16-0091270010389470" xlink:href="10.1177_0091270010389470-eq16.tif"/>
</disp-formula></p></list-item>
<list-item><p>where the model parameters, θ ={λ<sub><italic>pl</italic></sub>, <italic>k</italic>}, are given in by the estimated hazard models of TFPR or TMPR, <italic>C(t)</italic> is the plasma ibuprofen concentration at time <italic>t</italic>, and <italic>AUC</italic><sub><italic>0-t</italic></sub> is the plasma ibuprofen AUC from time 0 to <italic>t</italic>.</p></list-item>
<list-item><p>The median TFPR or TMPR value is the time <italic>T</italic><sub><italic>i</italic></sub> where <italic>Pr</italic>(<italic>t</italic> = <italic>T</italic><sub><italic>i</italic></sub>|θ) = 50%</p></list-item></list></list-item>
<list-item><p>The nomograms of median TFPR or TMPR are the contour plot of the estimated median TFPR or TMPR at different C<sub>max</sub> and T<sub>max</sub> combinations.</p></list-item>
</list>
</sec>
<sec id="section8-0091270010389470">
<title>Remedication</title>
<p>REMD nomograms correlating the 8-hour REMD rate with ibuprofen PK profiles were created by simulation. The simulation was done in S-plus using a procedure summarized as follows:</p>
<list id="list3-0091270010389470" list-type="order">
<list-item><p>A matrix of size <italic>n</italic> × <italic>m</italic> was created for a series of T<sub>max</sub> (length = <italic>n</italic>) values and a series of C<sub>max</sub> values (length = <italic>m</italic>). The T<sub>max</sub> selected for this simulation ranges from 0.2 to 3.0 hours in increments of 0.1 hour, and the C<sub>max</sub> ranges from 20 to 60 µg·mL<sup>−1</sup> in increments of 5 µg·mL<sup>−1</sup>. Approximately, doses were ranged from 170 mg to 1680 mg, and the ka values were ranged from 0.3 h<sup>−1</sup> to 46.7 h<sup>−1</sup>.</p></list-item>
<list-item><p>The 8-hour REMD rates for each C<sub>max</sub> and T<sub>max</sub> combination were simulated following the similar steps:</p>
<list id="list4-0091270010389470" list-type="bullet"><list-item><p>Assuming PK can be described by a first-order absorption model with lag time, combinations of ibuprofen dose (mg) and its first-order absorption rate constant ka (h<sup>−1</sup>) were created to meet the targeted C<sub>max</sub> and T<sub>max</sub> combination. An absorption lag time (<italic>T</italic><sub><italic>lag</italic></sub>) of 0.1 hours was selected to represent the faster absorption formulation and <italic>T</italic><sub><italic>lag</italic></sub> = 0.3 hours was selected to represent the slower absorption formulation. The time course of ibuprofen plasma concentration was calculated from dose, ka, T<sub>lag</sub>, V/F, and CL/F. V/F and CL/F values of ibuprofen were sampled from the parameters estimated from this study. Neither interindividual nor intraindividual variability were included in the PK calculations.</p></list-item>
<list-item><p>Pain relief profiles for 1000 subjects were simulated from the pain relief model with measurements at baseline and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, and 8 hours postdose. Interindividual variability was included in this simulation.</p></list-item>
<list-item><p>REMD rate at each interval was simulated by the REMD model (<xref ref-type="disp-formula" rid="disp-formula14-0091270010389470">Equation 14</xref>). The REMD fraction was estimated from the dropout rate of the 1000 patients at 8 hours postdose, with last observation carried forward (LOCF) applied to each patient.</p></list-item>
</list></list-item>
<list-item><p>The REMD nomogram is the contour plot of the 8-hour REMD rates at different T<sub>max</sub> and C<sub>max</sub> combinations.</p></list-item>
<list-item><p>Because of the limited number of sampling points, the level curves of the graph created by the S-plus contour plot function were jagged. To make the contours smooth, quadratic lines were fitted to each contour line, and the smoothed lines are shown in the REMD nomograms.</p></list-item>
</list>
</sec>
</sec>
<sec id="section9-0091270010389470" sec-type="results">
<title>Results</title>
<p>PK and efficacy data were collected from 30 patients in the ibuprofen effervescent group and 22 patients in the standard ibuprofen tablet group. Efficacy data (only) were obtained from 37 patients in the placebo group who had blood samples drawn. Mean age and sex ratio were balanced among the treatment arms.</p>
<p>All treatments in this study were well tolerated with no serious adverse events observed or reported. No clinically significant changes were observed in clinical laboratory results, vital signs, or physical examinations.</p>
<sec id="section10-0091270010389470">
<title>Ibuprofen PKs</title>
<p>Mean (±95% confidence interval [CI]) ibuprofen plasma concentrations of patients treated with either ibuprofen effervescent or standard ibuprofen tablets are illustrated in <xref ref-type="fig" rid="fig1-0091270010389470">Figure 1</xref>. PK parameters of the 2 ibuprofen groups are provided in <xref ref-type="table" rid="table1-0091270010389470">Table I</xref>. The T<sub>max</sub> of the effervescent ibuprofen group is approximately 0.32 ± 0.12 (mean ± SD) hours, which is much shorter than 1.37 ± 0.86 hours for the standard ibuprofen group. The mean maximum plasma ibuprofen concentration (C<sub>max</sub>) of the ibuprofen effervescent group is 49.3 ± 8.7 (mean ± SD) µg·mL<sup>−1</sup>, which is 60% higher than the 30.7 ± 8.6 µg·mL<sup>−1</sup> for standard ibuprofen.</p>
<fig id="fig1-0091270010389470" position="float">
<label>Figure 1.</label>
<caption><p>Mean (±95% confidence interval [CI]) ibuprofen plasma concentrations of patients treated with 400 mg ibuprofen effervescent tablets (IBU eff, N = 30) or standard ibuprofen (Std IBU, N = 22) tablets.</p></caption>
<graphic xlink:href="10.1177_0091270010389470-fig1.tif"/>
</fig>
<table-wrap id="table1-0091270010389470" position="float">
<label>Table I</label>
<caption><p>Pharmacokinetic Parameters (±SE) of Ibuprofen Effervescent and Standard Ibuprofen Tablets<sup><xref ref-type="table-fn" rid="table-fn2-0091270010389470">a</xref>,<xref ref-type="table-fn" rid="table-fn3-0091270010389470">b</xref></sup></p></caption>
<graphic alternate-form-of="table1-0091270010389470" xlink:href="10.1177_0091270010389470-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">IBU Eff 400 mg (n = 30)</th>
<th align="center">Std IBU 400 mg (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C<sub>max</sub> (µg·mL<sup>−1</sup>)<sup><xref ref-type="table-fn" rid="table-fn4-0091270010389470">c</xref></sup></td>
<td>49.3</td>
<td>30.7</td>
</tr>
<tr>
<td>T<sub>max</sub> (h)<sup><xref ref-type="table-fn" rid="table-fn4-0091270010389470">c</xref></sup></td>
<td>0.32</td>
<td>1.37</td>
</tr>
<tr>
<td>k<sub>a</sub> (h<sup>−1</sup>)</td>
<td>23.7 ± 0.19</td>
<td>1.78 ± 0.24</td>
</tr>
<tr>
<td>T<sub>lag</sub> (h)</td>
<td>0.14 ± 0.01</td>
<td>0.33 ± 0.16</td>
</tr>
<tr>
<td>V/F (L)</td>
<td>7.45 ± 0.03</td>
<td>8.12 ± 0.07</td>
</tr>
<tr>
<td>CL/F (L·h<sup>−1</sup>)</td>
<td>3.77 ± 0.06</td>
<td>3.66 ± 0.07</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(ka)</sub></td>
<td>0 FIX</td>
<td>1.14</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(Tlag)</sub></td>
<td>0.50</td>
<td>0.50</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(V/F)</sub></td>
<td>0.024</td>
<td>0.051</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(CL/F)</sub></td>
<td>0.095</td>
<td>0.046</td>
</tr>
<tr>
<td>σ<sup>2</sup></td>
<td>1.66</td>
<td>2.66</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010389470">
<p>IBU eff, ibuprofen effervescent; std IBU, standard ibuprofen.</p>
</fn>
<fn id="table-fn2-0091270010389470">
<label>a.</label>
<p>ω<sup>2</sup> are the variances of the random effect of the model parameters in log domain.</p>
</fn>
<fn id="table-fn3-0091270010389470">
<label>b.</label>
<p>σ<sup>2</sup> is the variance of the residual variability.</p>
</fn>
<fn id="table-fn4-0091270010389470">
<label>c.</label>
<p>Mean model predicted values.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The first-order absorption rate (<italic>k</italic><sub><italic>a</italic></sub>) of effervescent ibuprofen was estimated as 23.7 (h<sup>−1</sup>), equivalent to an absorption half-life of 1.75 minutes. T<sub>lag</sub> was estimated as 8.4 minutes. Within 15 minutes postdose (T<sub>lag</sub> + 4 absorption half-lives), 95% of the effervescent ibuprofen would be absorbed. V/F was estimated as 7.45 L, and clearance (CL/F) was estimated as 3.77 L·h<sup>−1</sup>, equivalent to an elimination half-life of 1.37 hours.</p>
<p>Absorption of the standard ibuprofen tablet was slower than that of effervescent ibuprofen. The first-order absorption rate constant was estimated as 1.78 h<sup>−1</sup>, equivalent to an absorption half-life of 0.4 hours. Absorption lag time was estimated as 19.8 minutes, which is approximately 2.4 times as long as the lag time of the effervescent formulation. Therefore, 95% absorption of the standard ibuprofen would occur at about 1.9 hours postdose, which is much longer than effervescent ibuprofen. The V/F was estimated as 8.12 L, and the clearance was estimated as 3.66 L·h<sup>−1</sup>, equivalent to an elimination half-life of 1.54 hours. The V/F and the elimination rate constant estimated for both effervescent ibuprofen and standard ibuprofen are very similar.</p>
<p>Model-predicted versus observed ibuprofen plasma concentration is illustrated in <xref ref-type="fig" rid="fig2-0091270010389470">Figure 2</xref>. The plots suggest that the model adequately describes the PK of single-dose oral effervescent ibuprofen or standard ibuprofen tablets.</p>
<fig id="fig2-0091270010389470" position="float">
<label>Figure 2.</label>
<caption>
<p>Observed and model predicted ibuprofen plasma concentration of patients treated with ibuprofen effervescent (left) or standard ibuprofen (right) tablets. Circles represent observed ibuprofen concentration, and the solid line is a reference of a perfect fit.</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig2.tif"/>
</fig>
</sec>
<sec id="section11-0091270010389470">
<title>Pain Relief</title>
<p>The pain relief model parameters are summarized in <xref ref-type="table" rid="table2-0091270010389470">Table II</xref>. Maximum drug effect (<italic>E</italic><sub><italic>max</italic></sub>) was estimated as 1.80 units on top of the placebo effect. The <italic>EC</italic><sub>50</sub> of the effect-site ibuprofen concentration was estimated as 10.2 µg·mL<sup>−1</sup>. The equilibrium rate constant, <italic>k</italic><sub><italic>eo</italic></sub>, was estimated as 1.49 h<sup>−1</sup>, equivalent to an equilibrium half-life of 28 minutes. Mean observed pain relief scores versus model predicted values are illustrated in <xref ref-type="fig" rid="fig3-0091270010389470">Figure 3</xref>. The plot suggests that Lemmens’ pain relief model<sup><xref ref-type="bibr" rid="bibr21-0091270010389470">21</xref></sup> adequately describes the mean pain relief scores following treatment with ibuprofen effervescent, standard ibuprofen, or placebo.</p>
<table-wrap id="table2-0091270010389470" position="float">
<label>Table II</label>
<caption>
<p>Pain Relief Model Parameters for Patients Treated With Ibuprofen Effervescent, Standard Ibuprofen, or Placebo<sup><xref ref-type="table-fn" rid="table-fn5-0091270010389470">a</xref>,<xref ref-type="table-fn" rid="table-fn6-0091270010389470">b</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0091270010389470" xlink:href="10.1177_0091270010389470-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">Estimate ± SE(n = 89)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P<sub>max</sub> (pain relief unit)</td>
<td>1.54 ± 0.12</td>
</tr>
<tr>
<td>K (h<sup>−1</sup>)</td>
<td>1.26 ± 0.06</td>
</tr>
<tr>
<td>K<sub>eo</sub> (h<sup>−1</sup>)</td>
<td>1.49 ± 0.20</td>
</tr>
<tr>
<td>E<sub>max</sub> (pain relief unit)</td>
<td>1.80 ± 0.24</td>
</tr>
<tr>
<td>EC<sub>50</sub> (µg·mL<sup>−1</sup>, effect-site)</td>
<td>10.2 ± 0.23</td>
</tr>
<tr>
<td>γ</td>
<td>2.0 ± 0.43</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>pmax</sub></td>
<td>1.30</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(k)</sub></td>
<td>3.76</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>log(keo)</sub></td>
<td>0.73</td>
</tr>
<tr>
<td>ω<sup>2</sup><sub>Emax</sub></td>
<td>1.11</td>
</tr>
<tr>
<td>σ<sup>2</sup></td>
<td>0.26</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0091270010389470">
<label>a.</label>
<p>ω<sup>2</sup> are the variances of the random effect of the parameters.</p>
</fn>
<fn id="table-fn6-0091270010389470">
<label>b.</label>
<p>σ<sup>2</sup> is the variance of the model residual.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-0091270010389470" position="float">
<label>Figure 3.</label>
<caption><p>Mean observed and model-fitted pain relief scores by treatment groups. Symbols represent the mean observed pain relief score of ibuprofen effervescent 400 mg (Δ), standard ibuprofen 400 mg (Δ), and placebo (<italic>+</italic>), and the error bars represent 95% confidence intervals (CIs). Lines represent the mean of model predicted values. Patients who rescued were included up to the time point of remedication (REMD; no LOCF).</p></caption>
<graphic xlink:href="10.1177_0091270010389470-fig3.tif"/>
</fig>
<p>The delayed effect of ibuprofen on pain relief is illustrated in <xref ref-type="fig" rid="fig4-0091270010389470">Figure 4</xref>. Pain relief is related directly to the effect-site ibuprofen concentration rather than plasma concentration. For patients treated with effervescent ibuprofen, effect-site concentrations increase much faster than in patients administered standard ibuprofen. Peak effect-site concentration occurred at 1 hour postdose for effervescent ibuprofen and 2 hours for standard ibuprofen. Between 0 and 2.5 hours, effect-site concentrations of patients treated with effervescent ibuprofen were greater than those with standard ibuprofen, which explains the faster pain relief observed with the former.</p>
<fig id="fig4-0091270010389470" position="float">
<label>Figure 4.</label>
<caption>
<p>Mean ibuprofen plasma concentrations and effect-site concentrations following treatment with ibuprofen effervescent or standard ibuprofen tablets.</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig4.tif"/>
</fig>
</sec>
<sec id="section12-0091270010389470">
<title>TFPR and TMPR</title>
<p><xref ref-type="table" rid="table3-0091270010389470">Table III</xref> summarizes the hazard model parameters of TFPR and TMPR (<xref ref-type="disp-formula" rid="disp-formula7-0091270010389470">Equation 7</xref>). For patients treated with placebo, hazard rates were estimated as 1.04 and 0.30 (events per hour) for TFPR and TMPR, respectively. Ibuprofen increases the hazard rates, thus decreasing TFPR and TMPR values. The slopes for ibuprofen effect on the hazard rates are 0.088 and 0.11 (mL·µg<sup>−1</sup>) for TFPR and TMPR, respectively. In approximation, an ibuprofen plasma concentration of 10 µg·mL<sup>−1</sup> would double the hazard rate of TFPR and TMPR. The impact of ibuprofen on TMPR is slightly higher than on TFPR. The hazard models of TFPR and TMPR were validated by simulation. The observed and model predicted median TFPR and TMPR values are provided in <xref ref-type="table" rid="table4-0091270010389470">Table IV</xref>. The survival curves of TFPR and TMPR are illustrated in <xref ref-type="fig" rid="fig5-0091270010389470">Figure 5</xref> and <xref ref-type="fig" rid="fig6-0091270010389470">Figure 6</xref>, respectively. The simulated results are consistent with the observed TFPR and TMPR values.</p>
<table-wrap id="table3-0091270010389470" position="float">
<label>Table III</label>
<caption>
<p>TFPR and TMPR Model Parameters (Mean and 95% Confidence Interval) of Patients Treated With Ibuprofen Effervescent, Standard Ibuprofen, or Placebo</p>
</caption>
<graphic alternate-form-of="table3-0091270010389470" xlink:href="10.1177_0091270010389470-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Model Parameter</th>
<th align="center">TFPR</th>
<th align="center">TMPR</th>
</tr>
</thead>
<tbody>
<tr>
<td>λ<sub>pl</sub> (events per hour)</td>
<td>1.04 (0.76, 1.31)</td>
<td>0.30 (0.17, 0.42)</td>
</tr>
<tr>
<td>k (1/µg·mL<sup>−1</sup>)</td>
<td>0.088 (0.042, 0.133)</td>
<td>0.11 (0.04, 0.18)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0091270010389470">
<p>TFPR, time to first perceptible relief; TMPR, time to meaningful pain relief.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0091270010389470" position="float">
<label>Table IV</label>
<caption><p>Model-Predicted and Observed Median Values of TFPR and TMPR for Patients Treated With Ibuprofen Effervescent, Standard Ibuprofen, or Placebo</p></caption>
<graphic alternate-form-of="table4-0091270010389470" xlink:href="10.1177_0091270010389470-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameter</th>
<th align="center">IBU eff 400 mg (n = 30)</th>
<th align="center">Std IBU 400 mg (n = 22)</th>
<th align="center">Placebo (n = 37)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median TFPR (h)</td>
<td>Predicted</td>
<td>0.23</td>
<td>0.51</td>
<td>0.69</td>
</tr>
<tr>
<td/>
<td>Observed (95% CI)</td>
<td>0.21 (0.17, 0.25)</td>
<td>0.44 (0.22, 1.15)</td>
<td>0.41 (0.27, 0.96)</td>
</tr>
<tr>
<td>Median TMPR (h)</td>
<td>Predicted</td>
<td>0.48</td>
<td>1.05</td>
<td>2.34</td>
</tr>
<tr>
<td/>
<td>Observed (95% CI)</td>
<td>0.48 (0.40, 0.72)</td>
<td>0.79 (0.39, 2.25)</td>
<td>1.90 (1.14, na)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0091270010389470">
<p>TFPR, time to first perceptible relief; TMPR, time to meaningful pain relief; IBU eff, ibuprofen effervescent; std IBU, standard ibuprofen.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig5-0091270010389470" position="float">
<label>Figure 5.</label>
<caption>
<p>Kaplan-Meier curves for time to first perceptible relief (TFPR) for ibuprofen effervescent, standard ibuprofen, or placebo. The thin lines are observed values and the thicker lines are model-simulated results.</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig5.tif"/>
</fig>
<fig id="fig6-0091270010389470" position="float">
<label>Figure 6.</label>
<caption>
<p>Kaplan-Meier curves for time to meaningful relief for ibuprofen effervescent, standard ibuprofen, or placebo. The thin lines are observed values and the thicker lines are model-simulated results.</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig6.tif"/>
</fig>
</sec>
<sec id="section13-0091270010389470">
<title>Remedication</title>
<p>Hazard rates for REMD are provided in <xref ref-type="table" rid="table5-0091270010389470">Table V</xref>. Because no subject remedicated at a pain relief level of 4 (complete pain relief), the hazard rate was set to 0 for this relief level. The hazard rates decreased with increasing pain relief score. At a pain relief level of 0 (no relief), the hazard rate of a patient needing REMD was estimated as 1.34 h<sup>−1</sup>, while at a pain relief level of 3 (a lot of pain relief) the hazard rate decreased to 0.034 h<sup>−1</sup>, a nearly 40-fold difference as the pain relief level increased from 0 to 3. As expected, the model suggests that increasing pain relief decreases the REMD rate.</p>
<table-wrap id="table5-0091270010389470" position="float">
<label>Table V</label>
<caption>
<p>Estimated Hazard Rates (±SE) of Remedication at Different Pain Relief Levels</p>
</caption>
<graphic alternate-form-of="table5-0091270010389470" xlink:href="10.1177_0091270010389470-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Pain Relief Score</th>
<th align="center">0</th>
<th align="center">1</th>
<th align="center">2</th>
<th align="center">3</th>
<th align="center">4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hazard rate (h<sup>−–1</sup>)</td>
<td>1.34 ± 0.18</td>
<td>0.38 ± 0.07</td>
<td>0.071 ± 0.023</td>
<td>0.034 ± 0.013</td>
<td>0<sup><xref ref-type="table-fn" rid="table-fn9-0091270010389470">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0091270010389470">
<label>a.</label>
<p>Fixed to 0 because no remedication required for complete pain relief.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The hazard model of REMD was evaluated by simulating the REMD rate based on the observed pain relief scores at each time point. <xref ref-type="fig" rid="fig7-0091270010389470">Figure 7</xref> compares the observed versus simulated REMD probability by treatment group. The simulated results agree with the observed REMD rate throughout the 0- to 8-hour time course for the ibuprofen arms, and the model gives a very good prediction of the 8-hour REMD rate of all the treatment groups. In the placebo arm, there is a slight under-prediction at the earlier hours, suggesting the REMD risk of placebo might be greater than the ibuprofen arms. Nevertheless, the misfit of earlier hours is not expected to affect the prediction of the 8-hour REMD rate.</p>
<fig id="fig7-0091270010389470" position="float">
<label>Figure 7.</label>
<caption>
<p>Observed remedication (REMD) probability (circles and error bars represent mean ±90% confidence intervals [CIs]) versus simulated values (solid lines) based on observed pain relief scores.</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig7.tif"/>
</fig>
</sec>
<sec id="section14-0091270010389470">
<title>Nomograms of TFPR and TMPR</title>
<p>Nomograms of TFPR and TMPR are provided in <xref ref-type="fig" rid="fig8-0091270010389470">Figure 8</xref> and <xref ref-type="fig" rid="fig9-0091270010389470">Figure 9</xref>, respectively. Both TFPR and TMPR decrease with increasing C<sub>max</sub> and decreasing T<sub>max</sub>. Because effervescent ibuprofen has an earlier T<sub>max</sub> and higher C<sub>max</sub> than standard ibuprofen, TFPR and TMPR values for subjects treated with effervescent ibuprofen are much earlier than for those treated with standard ibuprofen. To attain an even faster TFPR or TMPR, one would need to increase C<sub>max</sub> (eg, by increasing the dose) or decrease T<sub>max</sub> (eg, by enhancing the rate of absorption of a new formulation).</p>
<fig id="fig8-0091270010389470" position="float">
<label>Figure 8.</label>
<caption>
<p>TFPR nomograms for ibuprofen formulations with first-order absorption and lag times of 0.1 (top) and 0.3 (bottom) hours. Curves represent median TFPR (hour). Solid dots represent predicted TFPR values for ibuprofen effervescent (top) and standard ibuprofen (bottom).</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig8.tif"/>
</fig>
<fig id="fig9-0091270010389470" position="float">
<label>Figure 9.</label>
<caption>
<p>TMPR nomograms for ibuprofen formulations with first-order absorption and lag times of 0.1 (top) and 0.3 (bottom) hours. Curves represent median TMPR (hour). Solid dots represent predicted TMPR values for ibuprofen effervescent (top) and standard ibuprofen (bottom).</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig9.tif"/>
</fig>
</sec>
<sec id="section15-0091270010389470">
<title>Nomogram for REMD</title>
<p>REMD nomograms are illustrated in <xref ref-type="fig" rid="fig10-0091270010389470">Figure 10</xref>. REMD rates decrease with increasing C<sub>max</sub> and T<sub>max</sub>. At the same dose level, a faster absorption formulation has a higher C<sub>max</sub> but a lower T<sub>max</sub>; therefore, the REMD rate is less sensitive to the absorption rate.</p>
<fig id="fig10-0091270010389470" position="float">
<label>Figure 10.</label>
<caption>
<p>Remedication (REMD) nomograms for ibuprofen formulations with first-order absorption and lag times of 0.1 (top) and 0.3 (bottom) hours. Curves represent REMD rates at 8 hours postdose. Solid dots represent predicted REMD rates for ibuprofen effervescent (top) and standard ibuprofen (bottom).</p>
</caption>
<graphic xlink:href="10.1177_0091270010389470-fig10.tif"/>
</fig>
<p>Observed REMD rates at 8 hours were 47% for effervescent ibuprofen and 55% for standard ibuprofen. The REMD rate estimated by the nomograms matches the observed value of the standard ibuprofen group, but slightly overestimates that of the effervescent ibuprofen group.</p>
</sec>
</sec>
<sec id="section16-0091270010389470" sec-type="discussion">
<title>Discussion</title>
<p>The PK profiles of effervescent ibuprofen and standard ibuprofen tablets from this study are generally consistent with those reported previously for these 2 types of formulations. The C<sub>max</sub> and T<sub>max</sub> of Nurofen tablets observed in this study are similar to those reported in the literature.<sup><xref ref-type="bibr" rid="bibr10-0091270010389470">10</xref>,<xref ref-type="bibr" rid="bibr22-0091270010389470">22</xref></sup> In contrast, Saano et al<sup><xref ref-type="bibr" rid="bibr19-0091270010389470">19</xref></sup> reported a C<sub>max</sub> of 31.7 µg·mL<sup>−1</sup> and a T<sub>max</sub> of 1.91 hours for another ibuprofen effervescent tablet (2 × 200 mg), which represents considerably slower absorption than the current ibuprofen effervescent formulation (respective values of 49.3 µg·mL<sup>−1</sup> and 0.32 hours). Altomare et al<sup><xref ref-type="bibr" rid="bibr20-0091270010389470">20</xref></sup> reported a C<sub>max</sub> of 27.2 µg·mL<sup>−1</sup> and T<sub>max</sub> of 0.5 hours for another effervescent ibuprofen formulation at a dose of 200 mg. Considering dose proportionality, their result for C<sub>max</sub> is similar to that observed in the current study, but their T<sub>max</sub> value is slightly later. In comparison with other rapidly absorbed ibuprofen formulations, the C<sub>max</sub> observed for the current ibuprofen effervescent formulation (49.3 µg·mL<sup>−1</sup>) is similar to that of the same dose of ibuprofen liquigels (49.7 µg·mL<sup>−1</sup>) and ibuprofen lysinate (43.2 µg·mL<sup>−1</sup>), whereas the T<sub>max</sub> is slightly faster (0.32 hours vs 0.54 hours for both liquigels and lysinate).<sup><xref ref-type="bibr" rid="bibr10-0091270010389470">10</xref></sup> Similar observations can be made when the present data are compared with data from another PK study of ibuprofen liquigels and lysinate,<sup><xref ref-type="bibr" rid="bibr22-0091270010389470">22</xref></sup> or if compared with 2 other rapidly absorbed ibuprofen salts (ibuprofen sodium and arginate; respective T<sub>max</sub> values of 0.70 and 0.56 hours).<sup><xref ref-type="bibr" rid="bibr23-0091270010389470">23</xref></sup> Although PK results can vary across studies, the data suggest that the rate of absorption of the current effervescent ibuprofen tablet is at least as fast as that of other rapidly absorbed oral ibuprofen formulations.</p>
<p>The 1-compartment PK model with first-order absorption, first-order elimination, and an absorption lag time, adequately describes the oral administration of effervescent ibuprofen and standard ibuprofen. Similar PK models have been used for ibuprofen tablet and suspension formulations in children.<sup><xref ref-type="bibr" rid="bibr24-0091270010389470">24</xref></sup> A 2-compartment model was utilized in other studies.<sup><xref ref-type="bibr" rid="bibr25-0091270010389470">25</xref>,<xref ref-type="bibr" rid="bibr26-0091270010389470">26</xref></sup> Troconiz et al<sup><xref ref-type="bibr" rid="bibr26-0091270010389470">26</xref></sup> used a 2-compartment system to estimate a plasma ibuprofen clearance (CL/F) of 4.05 L.h<sup>−1</sup>, which is similar to the value estimated in this study. Absorption of ibuprofen is not necessarily first-order.<sup><xref ref-type="bibr" rid="bibr27-0091270010389470">27</xref></sup> In fact, a zero-order absorption model might be more accurate in describing the fast absorption of effervescent ibuprofen tablet. However, for the convenience of comparing the efficacy outcomes of these 2 different formulations, the same PK model structure was used for both ibuprofen effervescent and standard ibuprofen tablets.</p>
<p>The pain relief model treats the 5-point ordered categorical pain relief score as continuous data. Although there is a precedent modeling it as a continuous variable for ibuprofen,<sup><xref ref-type="bibr" rid="bibr21-0091270010389470">21</xref></sup> an alternate method retains the categorical nature of the data.<sup><xref ref-type="bibr" rid="bibr28-0091270010389470">28</xref></sup> Both methods have the disadvantage that the distance between pain relief scores (or between pain relief probabilities) is modeled empirically. The categorical model has better theoretical properties. However, the categorical model would place more emphasis on fitting extreme pain relief scores (eg, scores of 0 and 4), whereas the continuous model would emphasize fitting the common pain scores (eg, 2 and 3), which are especially relevant at the time of REMD. Therefore, it is not surprising that the model of continuous pain relief describes the mean pain relief score and REMD probability accurately, even perhaps more accurately than would a categorical model. The ibuprofen EC50 (effect-site) for pain relief estimated from this study is 10.2 µg·mL<sup>−1</sup>, which is at a similar level of the 6.4 µg·mL<sup>−1</sup> reported by Lemmens et al.<sup><xref ref-type="bibr" rid="bibr21-0091270010389470">21</xref></sup></p>
<p>Taking into account the relatively small sample size, the results for TFPR and TMPR in the present study suggest that ibuprofen effervescent has a faster onset of analgesia than standard ibuprofen. TFPR and TMPR were 13 minutes and 29 minutes, respectively, for effervescent ibuprofen, and 26 minutes and 47 minutes, respectively, for standard ibuprofen. In another dental pain study, Mehlisch et al<sup><xref ref-type="bibr" rid="bibr16-0091270010389470">16</xref></sup> obtained respective TFPR and TMPR values of 14 and 31 minutes for ibuprofen arginate and 16 and 58 minutes for conventional ibuprofen. In 2 other studies comparing ibuprofen arginate to standard ibuprofen in the dental pain model, Desjardins et al<sup><xref ref-type="bibr" rid="bibr15-0091270010389470">15</xref></sup> reported respective TFPR and TMPR values of 9 and 24 minutes for the arginate salt and 14 and 48 minutes for standard ibuprofen, while Black et al<sup><xref ref-type="bibr" rid="bibr14-0091270010389470">14</xref></sup> obtained respective values of 10 and 28 minutes for ibuprofen arginate and 12 and 44 minutes for conventional ibuprofen tablets. Based on these data, and considering the variability of onset values across studies, it appears that the current effervescent ibuprofen formulation has an onset of analgesia as fast as sodium arginate. The data also suggest that faster acting forms of ibuprofen demonstrate a greater benefit in TMPR than in TFPR, which is consistent with the modeling performed in this study. This may be because of the greater effect of placebo on TFPR than on TMPR,<sup><xref ref-type="bibr" rid="bibr14-0091270010389470">14</xref></sup> presumably because “meaningful” pain relief is a more robust measure of relief.</p>
<p>A previous dental pain publication modeled TMPR as a dose-dependent distribution conditional on the REMD status.<sup><xref ref-type="bibr" rid="bibr29-0091270010389470">29</xref></sup> Modeling TFPR and TMPR as survival variables that vary linearly with plasma concentrations is a common technique in modeling, which more directly links back to dose and PK profile. Utilizing linear interpolations between individual plasma concentrations as the input to such a model makes this method especially practical. This method allows PD models to be developed for time-to-event data for fast-acting drugs with variable PK profiles, especially during absorption.</p>
<p>The 8-hour REMD rates observed in this study were 47%, 55%, and 81% for effervescent ibuprofen, standard ibuprofen, and placebo, respectively. Mehlisch et al<sup><xref ref-type="bibr" rid="bibr16-0091270010389470">16</xref></sup> reported 4-hour REMD rates of 33% for patients treated with ibuprofen arginate 400 mg and 32% for patients treated with conventional ibuprofen 400 mg. The 4-hour REMD rates observed in this study were 17% for effervescent ibuprofen and 36% for standard ibuprofen. The limited data available suggest that the REMD rate of ibuprofen effervescent, but not ibuprofen arginate, may be lower than that of conventional ibuprofen.</p>
<p>Nomograms illustrate the relationship of TFPR, TMPR, and REMD rate with the rate of ibuprofen absorption, which could provide useful guidance in the development of new, faster acting ibuprofen formulations. C<sub>max</sub> and T<sub>max</sub> were selected as the parameters representing the absorption characteristics of an ibuprofen formulation, therefore, the nomograms only apply to those formulations for which ibuprofen plasma concentration versus time data could be described by a 1-compartment system with a first-order absorption, a first-order elimination, and an absorption lag time. For other complicated formulations, such as those with extended-release properties, a new nomogram would need to be developed by simulating that specific PK profile. The application of nomograms to quickly estimate the PD behavior of new formulations is, from the authors’ perspective, a novel application of PKPD modeling.</p>
<p>The nomograms of the onset and offset of dental pain relief suggest that an even faster absorption rate could provide earlier TFPR and TMPR values. The model also suggests that faster onset could also be achieved by higher doses of ibuprofen (higher C<sub>max</sub>). The REMD rate also decreases with a faster absorption rate, but the change is less sensitive to an increase in absorption rate than is TFPR or TMPR.</p>
</sec>
<sec id="section17-0091270010389470" sec-type="conclusions">
<title>Conclusion</title>
<p>Effervescent ibuprofen is absorbed faster than standard ibuprofen in postoperative dental pain patients, resulting in earlier TFPR and TMPR for the former than the latter. The REMD rate was also lower in patients treated with ibuprofen effervescent. The nomograms developed in this study correlate with the onset and offset of dental pain relief with ibuprofen PK profiles, and may provide guidance in the development of novel, potentially faster acting ibuprofen formulations.</p>
</sec>
</body>
<back>
<ack><p>The authors’ gratefully acknowledge the skillful execution of the clinical portion of this research led by Dr Stephen Daniels, Dale Redden, Colleen Coelho, and Kristin Southerden at SCIREX/Premier Research Centers.</p></ack>
<fn-group>
<fn fn-type="presented-at">
<p>A preliminary report of this research was presented at the 38th Annual Meeting of the American College of Clinical Pharmacology, in San Antonio Texas, September 13 to 15, 2009.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work was funded by Pfizer Consumer Healthcare. Shyamalie Jayawardena, Paul Desjardins, Geraldine Doyle, and David Kellstein are employees of Pfizer Consumer Healthcare. Hanbin Li, Jaap Mandema, and Russell Wada are employees of Quantitative Solutions Inc, a contract consulting service provider of Pfizer Consumer Healthcare.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010389470">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>N</given-names></name>
</person-group>. <article-title>Ibuprofen: a journey from prescription to over-the-counter use</article-title>. <source>J R Soc Med</source>. <year>2007</year>;<volume>48</volume>:<fpage>2</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010389470">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>N</given-names></name>
</person-group>. <article-title>Forty years of ibuprofen use</article-title>. <source>Int J Clin Pract Suppl</source>. <year>2003</year>;<volume>135</volume>:<fpage>28</fpage>-<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010389470">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>SA</given-names></name>
<name><surname>Schachtel</surname><given-names>BP</given-names></name>
<name><surname>Goldman</surname><given-names>E</given-names></name>
<name><surname>Gelb</surname><given-names>S</given-names></name>
<name><surname>Cohn</surname><given-names>P</given-names></name>
</person-group>. <article-title>Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study</article-title>. <source>J Clin Pharmacol</source>. <year>1989</year>;<volume>29</volume>:<fpage>1026</fpage>-<lpage>1030</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010389470">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schachtel</surname><given-names>BP</given-names></name>
<name><surname>Furey</surname><given-names>SA</given-names></name>
<name><surname>Thoden</surname><given-names>WR</given-names></name>
</person-group>. <article-title>Nonprescription ibuprofen and acetaminophen in the treatment of tension-type headache</article-title>. <source>J Clin Pharmacol</source>. <year>1996</year>;<volume>36</volume>:<fpage>1120</fpage>-<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010389470">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>RP</given-names></name>
<name><surname>Lockhart</surname><given-names>EA</given-names></name>
<name><surname>Bruno</surname><given-names>P</given-names></name>
</person-group>. <article-title>Delayed onset muscle soreness (DOMS)-a new pain model to compare OTC analgesics [abstract]</article-title>. <source>Med Sci Sports Exerc</source>. <year>1994</year>;<volume>14</volume>:<fpage>26</fpage>.</citation>
</ref>
<ref id="bibr6-0091270010389470">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schachtel</surname><given-names>BP</given-names></name>
<name><surname>Fillingim</surname><given-names>JM</given-names></name>
<name><surname>Thoden</surname><given-names>WR</given-names></name>
<name><surname>Lane</surname><given-names>AC</given-names></name>
<name><surname>Baybutt</surname><given-names>RI</given-names></name>
</person-group>. <article-title>Sore throat pain in the evaluation of mild analgesics</article-title>. <source>Clin Pharmacol Ther</source>. <year>1988</year>;<volume>44</volume>:<fpage>704</fpage>-<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010389470">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schachtel</surname><given-names>BP</given-names></name>
<name><surname>Thoden</surname><given-names>WR</given-names></name>
<name><surname>Baybutt</surname><given-names>RI</given-names></name>
</person-group>. <article-title>Ibuprofen and acetaminophen in the relief of postpartum episiotomy pain</article-title>. <source>J Clin Pharmacol</source>. <year>1989</year>;<volume>29</volume>:<fpage>550</fpage>-<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010389470">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>SA</given-names></name>
<name><surname>Needle</surname><given-names>SE</given-names></name>
<name><surname>Kruger</surname><given-names>GO</given-names></name>
</person-group>. <article-title>Comparative analgesic potency of aspirin and ibuprofen</article-title>. <source>J Oral Surg</source>. <year>1977</year>;<volume>35</volume>:<fpage>898</fpage>-<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010389470">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laska</surname><given-names>EM</given-names></name>
<name><surname>Sunshine</surname><given-names>A</given-names></name>
<name><surname>Marrero</surname><given-names>I</given-names></name>
<name><surname>Olson</surname><given-names>N</given-names></name>
<name><surname>Siegel</surname><given-names>C</given-names></name>
<name><surname>McCormick</surname><given-names>N</given-names></name>
</person-group>. <article-title>The correlation between blood levels of ibuprofen and clinical analgesic response</article-title>. <source>Clin Pharmacol Ther</source>. <year>1986</year>;<volume>40</volume>:<fpage>1</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010389470">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schettler</surname><given-names>T</given-names></name>
<name><surname>Paris</surname><given-names>S</given-names></name>
<name><surname>Pellett</surname><given-names>M</given-names></name>
<name><surname>Kidner</surname><given-names>S</given-names></name>
<name><surname>Wilkinson</surname><given-names>D</given-names></name>
</person-group>. <article-title>Comparative pharmacokinetics of 2 fast-dissolving oral ibuprofen formulations and a regular-release ibuprofen tablet in healthy volunteers</article-title>. <source>Clin Drug Investig</source>. <year>2001</year>;<volume>21</volume>(<issue>6</issue>):<fpage>73</fpage>-<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010389470">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hersh</surname><given-names>EV</given-names></name>
<name><surname>Levin</surname><given-names>LM</given-names></name>
<name><surname>Cooper</surname><given-names>SA</given-names></name>
<etal/>
</person-group>. <article-title>Ibuprofen liquigel for oral surgery pain</article-title>. <source>Clin Ther</source>. <year>2000</year>;<volume>22</volume>:<fpage>1306</fpage>-<lpage>1318</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010389470">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Packman</surname><given-names>B</given-names></name>
<name><surname>Packman</surname><given-names>E</given-names></name>
<name><surname>Doyle</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache</article-title>. <source>Headache</source>. <year>2000</year>;<volume>40</volume>: <fpage>561</fpage>-<lpage>567</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010389470">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olson</surname><given-names>NZ</given-names></name>
<name><surname>Otero</surname><given-names>AM</given-names></name>
<name><surname>Marrero</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain</article-title>. <source>J Clin Pharmacol</source>. <year>2001</year>;<volume>41</volume>:<fpage>1238</fpage>-<lpage>1247</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010389470">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>P</given-names></name>
<name><surname>Max</surname><given-names>MB</given-names></name>
<name><surname>Desjardins</surname><given-names>P</given-names></name>
<name><surname>Norwood</surname><given-names>T</given-names></name>
<name><surname>Ardia</surname><given-names>A</given-names></name>
<name><surname>Pallotta</surname><given-names>T</given-names></name>
</person-group>. <article-title>A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain</article-title>. <source>Clin Ther</source>. <year>2002</year>;<volume>24</volume>:<fpage>1072</fpage>-<lpage>1089</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010389470">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Desjardins</surname><given-names>P</given-names></name>
<name><surname>Black</surname><given-names>P</given-names></name>
<name><surname>Papageorge</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2002</year>;<volume>58</volume>:<fpage>387</fpage>-<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010389470">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehlisch</surname><given-names>DR</given-names></name>
<name><surname>Ardia</surname><given-names>A</given-names></name>
<name><surname>Pallotta</surname><given-names>T</given-names></name>
</person-group>. <article-title>A controlled comparative study of ibuprofen arginate versus conventional ibuprofen in the treatment of postoperative dental pain</article-title>. <source>J Clin Pharmacol</source>. <year>2002</year>;<volume>42</volume>:<fpage>904</fpage>-<lpage>911</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010389470">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schleier</surname><given-names>P</given-names></name>
<name><surname>Prochnau</surname><given-names>A</given-names></name>
<name><surname>Schmidt-Westhausen</surname><given-names>AM</given-names></name>
<etal/></person-group>. <article-title>Ibuprofen sodium dihydrate, an ibuprofen formulation with improved absorption characteristics, provides faster and greater pain relief than ibuprofen acid</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2007</year>;<volume>45</volume>:<fpage>89</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010389470">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>NK</given-names></name>
<name><surname>Kindelan</surname><given-names>JD</given-names></name>
<name><surname>Hutchinson</surname><given-names>D</given-names></name>
<name><surname>Lancaster</surname><given-names>L</given-names></name>
</person-group>. <article-title>A study to compare ibuprofen effervescent granules with ibuprofen tablets in the treatment of acute dental pain</article-title>. <source>Prim Dent Care</source>. <year>1994</year>;<volume>1</volume>:<fpage>5</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010389470">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saano</surname><given-names>V</given-names></name>
<name><surname>Paronen</surname><given-names>P</given-names></name>
<name><surname>Peura</surname><given-names>P</given-names></name>
<name><surname>Vidgren</surname><given-names>M</given-names></name>
</person-group>. <article-title>Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers</article-title>. <source>Int J Clin Pharmacol Ther Toxicol</source>. <year>1991</year>;<volume>29</volume>:<fpage>381</fpage>-<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010389470">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altomare</surname><given-names>E</given-names></name>
<name><surname>Vendemiale</surname><given-names>G</given-names></name>
<name><surname>Benvenuti</surname><given-names>C</given-names></name>
<name><surname>Andreatta</surname><given-names>P</given-names></name>
</person-group>. <article-title>Bioavailability of a new effervescent tablet of ibuprofen in healthy volunteers</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1997</year>;<volume>52</volume>:<fpage>505</fpage>-<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr21-0091270010389470">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemmens</surname><given-names>H</given-names></name>
<name><surname>Stanski</surname><given-names>DR</given-names></name>
<name><surname>Cooper</surname><given-names>S</given-names></name>
<name><surname>Karpow</surname><given-names>S</given-names></name>
</person-group>. <article-title>Pharmacokinetic-Pharmacodynamics (PK/PD) of Ibuprofen in dental pain</article-title>. <source>J Clin Pharmacol</source>. <year>1996</year>;<volume>36</volume>:<fpage>856</fpage>.</citation>
</ref>
<ref id="bibr22-0091270010389470">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bramlage</surname><given-names>P</given-names></name>
<name><surname>Goldis</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers</article-title>. <source>BMC Pharmacol</source>. <year>2008</year>;<volume>8</volume>:<fpage>18</fpage>.</citation>
</ref>
<ref id="bibr23-0091270010389470">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorgel</surname><given-names>F</given-names></name>
<name><surname>Fuhr</surname><given-names>U</given-names></name>
<name><surname>Minic</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2005</year>;<volume>43</volume>:<fpage>140</fpage>-<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr24-0091270010389470">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beringer</surname><given-names>P</given-names></name>
<name><surname>Aminimanizani</surname><given-names>A</given-names></name>
<name><surname>Synold</surname><given-names>T</given-names></name>
<name><surname>Scott</surname><given-names>C</given-names></name>
</person-group>. <article-title>Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis</article-title>. <source>Ther Drug Monit</source>. <year>2002</year>;<volume>24</volume>:<fpage>315</fpage>-<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr25-0091270010389470">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname><given-names>KS</given-names></name>
<name><surname>Gernaat</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Pharmacokinetics of ibuprofen</article-title>. <source>Am J Med</source>. <year>1984</year>;<volume>77</volume>:<fpage>40</fpage>-<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr26-0091270010389470">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Troconiz</surname><given-names>IF</given-names></name>
<name><surname>Armenteros</surname><given-names>S</given-names></name>
<name><surname>Planelles</surname><given-names>MV</given-names></name>
<name><surname>Benitez</surname><given-names>J</given-names></name>
<name><surname>Calvo</surname><given-names>R</given-names></name>
<name><surname>Dominguez</surname><given-names>R</given-names></name>
</person-group>. <article-title>Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen</article-title>. <source>Clin Pharmacokinet</source>. <year>2000</year>;<volume>38</volume>:<fpage>505</fpage>-<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr27-0091270010389470">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>JG</given-names></name>
<name><surname>Albert</surname><given-names>KS</given-names></name>
<name><surname>Szpunar</surname><given-names>GJ</given-names></name>
<name><surname>Lockwood</surname><given-names>GF</given-names></name>
</person-group>. <article-title>Pharmacokinetics of ibuprofen in man IV: absorption and disposition</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1984</year>;<volume>12</volume>:<fpage>381</fpage>-<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr28-0091270010389470">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mandema</surname><given-names>JW</given-names></name>
<name><surname>Stanski</surname><given-names>DR</given-names></name>
</person-group>. <article-title>Population pharmacodynamic model for ketorolac analgesia</article-title>. <source>Clin Pharmacol Ther</source>. <year>1996</year>;<volume>60</volume>:<fpage>619</fpage>-<lpage>635</lpage>.</citation>
</ref>
<ref id="bibr29-0091270010389470">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rohatagi</surname><given-names>S</given-names></name>
<name><surname>Kastrissios</surname><given-names>H</given-names></name>
<name><surname>Sasahara</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain</article-title>. <source>Br J Clin Pharmacol</source>. <year>2008</year>;<volume>66</volume>:<fpage>60</fpage>-<lpage>70</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>